Robert Barrow Sells 29,208 Shares of Definium Therapeutics (NASDAQ:DFTX) Stock

Definium Therapeutics, Inc. (NASDAQ:DFTX) CEO Robert Barrow sold 29,208 shares of the stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $1,315,236.24. Following the completion of the sale, the chief executive officer owned 1,098,246 shares in the company, valued at approximately $49,454,017.38. This trade represents a 2.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Definium Therapeutics Price Performance

Shares of DFTX stock opened at $44.95 on Friday. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.15. Definium Therapeutics, Inc. has a 12-month low of $6.40 and a 12-month high of $47.01. The firm has a fifty day moving average of $24.59 and a 200-day moving average of $19.36. The firm has a market capitalization of $4.48 billion, a price-to-earnings ratio of -18.05 and a beta of 2.37.

Definium Therapeutics (NASDAQ:DFTX) last issued its quarterly earnings data on Friday, May 8th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.23). On average, equities research analysts forecast that Definium Therapeutics, Inc. will post -2.29 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Stifel Nicolaus set a $30.00 price objective on Definium Therapeutics and gave the company a “buy” rating in a report on Thursday, April 16th. Canaccord Genuity Group set a $60.00 target price on Definium Therapeutics in a research note on Monday, June 22nd. Robert W. Baird raised their target price on shares of Definium Therapeutics from $37.00 to $57.00 and gave the stock an “outperform” rating in a report on Tuesday, June 23rd. Citigroup reaffirmed a “buy” rating on shares of Definium Therapeutics in a research note on Monday, June 22nd. Finally, JonesTrading upped their price target on shares of Definium Therapeutics from $61.00 to $74.00 and gave the company a “buy” rating in a report on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Definium Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $47.08.

Definium Therapeutics News Roundup

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Definium said its Phase III depression program delivered positive results, a key catalyst that can support optimism about eventual approval and commercialization. Definium raises $805 million after positive Phase III depression data
• Positive Sentiment: The company closed an upsized public offering, raising $805 million, which strengthens its balance sheet and reduces near-term financing risk. Definium Therapeutics Announces Closing of $805 Million Upsized Public Offering
• Neutral Sentiment: Several insiders, including the CEO and CFO, sold shares at $45.03. Insider selling can sometimes pressure sentiment, but the transactions were relatively small compared with their remaining holdings. CEO insider filing
• Neutral Sentiment: Market commentary and analyst writeups also pointed to the stock’s sharp move higher after the Phase III news, reinforcing the view that investors are reacting to the clinical-data catalyst. Why Definium Therapeutics, Inc.’s (DFTX) Stock Is Up 15.35%
• Negative Sentiment: Heavy insider selling from multiple executives may temper enthusiasm, as some investors could interpret it as a sign management views the stock as fully valued near recent highs.

Institutional Trading of Definium Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of DFTX. Russell Investments Group Ltd. boosted its position in shares of Definium Therapeutics by 110.4% during the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after buying an additional 2,003 shares during the period. BNP Paribas Financial Markets grew its holdings in shares of Definium Therapeutics by 56.0% during the second quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock worth $55,000 after buying an additional 3,020 shares in the last quarter. Flagship Harbor Advisors LLC acquired a new stake in Definium Therapeutics in the 4th quarter valued at approximately $117,000. FNY Investment Advisers LLC acquired a new stake in Definium Therapeutics in the 3rd quarter valued at approximately $107,000. Finally, Caxton Associates LLP bought a new stake in Definium Therapeutics in the 3rd quarter valued at approximately $126,000. Institutional investors and hedge funds own 27.91% of the company’s stock.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.